Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial.

Cohen CW, Fontaine KR, Arend RC, Soleymani T, Gower BA.

Nutrients. 2018 Aug 30;10(9). pii: E1187. doi: 10.3390/nu10091187.

2.

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog TJ.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0095. doi: 10.1634/theoncologist.2018-0095. [Epub ahead of print]

PMID:
30139839
3.

A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.

Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath Iii CA, Huh WK, Bevis KS, Kim KH, Straughn JM Jr, Gower BA.

J Nutr. 2018 Aug 1;148(8):1253-1260. doi: 10.1093/jn/nxy119.

PMID:
30137481
4.

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.

Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, van Waardenburg RCAM, Alvarez RD, Yoon KJ.

Cancer Lett. 2018 Nov 1;436:75-86. doi: 10.1016/j.canlet.2018.08.015. Epub 2018 Aug 16.

PMID:
30120964
5.

Overcoming immune suppression with epigenetic modification in ovarian cancer.

McCaw TR, Randall TD, Arend RC.

Transl Res. 2018 Jun 23. pii: S1931-5244(18)30099-9. doi: 10.1016/j.trsl.2018.06.003. [Epub ahead of print] Review.

PMID:
30048638
6.

Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.

Wu J, Blair J, Izevbigie OC, Wright NC, Arend RC.

Gynecol Oncol. 2018 Sep;150(3):494-500. doi: 10.1016/j.ygyno.2018.06.024. Epub 2018 Jun 30.

PMID:
29970241
7.

Endometrial cancer: Molecular markers and management of advanced stage disease.

Arend RC, Jones BA, Martinez A, Goodfellow P.

Gynecol Oncol. 2018 Sep;150(3):569-580. doi: 10.1016/j.ygyno.2018.05.015. Epub 2018 May 27. Review.

PMID:
29843906
8.

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Jones BA, Varambally S, Arend RC.

Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437. Review.

PMID:
29726819
9.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

10.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.

PMID:
29523763
11.

Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.

Van Arsdale AR, Arend RC, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS.

Cancer Med. 2018 Mar;7(3):616-625. doi: 10.1002/cam4.1335. Epub 2018 Feb 18.

12.

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC.

Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395.

13.

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.

Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC.

Gynecol Oncol Rep. 2017 Mar 21;20:81-86. doi: 10.1016/j.gore.2017.03.007. eCollection 2017 May. Review.

14.

B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.

Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.

15.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

16.

Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

Craig ER, Londoño AI, Norian LA, Arend RC.

Gynecol Oncol. 2016 Dec;143(3):674-683. doi: 10.1016/j.ygyno.2016.10.005. Epub 2016 Oct 15. Review.

17.

The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.

Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MG, Arend RC, Yoon KJ, Klug CA, Bullard DC, Kesterson RA, Oliver PG, O'Connor AK, Yoder BK, Bellis SL.

Cancer Res. 2016 Jul 1;76(13):3978-88. doi: 10.1158/0008-5472.CAN-15-2834. Epub 2016 May 23.

18.

Ovarian cancer and the immune system - The role of targeted therapies.

Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC.

Gynecol Oncol. 2016 Aug;142(2):349-56. doi: 10.1016/j.ygyno.2016.05.007. Epub 2016 May 23. Review.

PMID:
27174875
19.

Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, Grizzle WE, McGwin G Jr, Gangrade A, Straughn JM Jr, Buchsbaum DJ.

Lab Invest. 2016 Feb;96(2):249-59. doi: 10.1038/labinvest.2015.150. Epub 2015 Dec 14.

20.

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.

Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.

PMID:
26303225
21.

Niclosamide Analogs for Treatment of Ovarian Cancer.

Walters Haygood CL, Arend RC, Gangrade A, Chettiar S, Regan N, Hassmann CJ 2nd, Li PK, Hidalgo B, Straughn JM Jr, Buchsbaum DJ.

Int J Gynecol Cancer. 2015 Oct;25(8):1377-85. doi: 10.1097/IGC.0000000000000506.

PMID:
26186072
22.

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ.

World J Stem Cells. 2014 Sep 26;6(4):441-7. doi: 10.4252/wjsc.v6.i4.441. Review.

23.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
24.

Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.

Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ.

Cancer Lett. 2014 Jul 10;349(1):8-14. doi: 10.1016/j.canlet.2014.04.003. Epub 2014 Apr 13. Review.

25.

Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.

Doo DW, Erickson BK, Arend RC, Conner MG, Huh WK, Leath CA 3rd.

Gynecol Oncol. 2014 May;133(2):234-7. doi: 10.1016/j.ygyno.2014.03.002. Epub 2014 Mar 11.

PMID:
24631447
26.

Effect of niclosamide on basal-like breast cancers.

Londoño-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, Lobuglio AF, Li Y, Buchsbaum DJ.

Mol Cancer Ther. 2014 Apr;13(4):800-11. doi: 10.1158/1535-7163.MCT-13-0555. Epub 2014 Feb 19.

27.

The Wnt/β-catenin pathway in ovarian cancer: a review.

Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2013 Dec;131(3):772-9. doi: 10.1016/j.ygyno.2013.09.034. Epub 2013 Oct 11. Review.

PMID:
24125749
28.

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.

Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD.

Gynecol Oncol. 2013 Nov;131(2):493-8. doi: 10.1016/j.ygyno.2013.07.080. Epub 2013 Jul 14. Review.

PMID:
23863359
29.

Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.

Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO.

Am J Obstet Gynecol. 2010 Sep;203(3):242.e1-5. doi: 10.1016/j.ajog.2010.04.046. Epub 2010 Jun 3.

30.

Extragenital adenosarcoma: a case report, review of the literature, and management discussion.

Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL.

Gynecol Oncol. 2009 Dec;115(3):472-5. doi: 10.1016/j.ygyno.2009.07.033. Epub 2009 Aug 26.

31.

Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, Goldberg GL.

Am J Obstet Gynecol. 2009 Apr;200(4):457.e1-5. doi: 10.1016/j.ajog.2008.12.012. Epub 2009 Feb 6.

Supplemental Content

Loading ...
Support Center